

# **Europe Liquid Biopsy Market By Offering (Testing Services, Kits, Platform, Other Consumables), By Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Others), By Application (Oncological, Non-Oncological), By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies), By Country, Competition, Forecast and Opportunities, 2020-2030F**

<https://marketpublishers.com/r/EE35B74B7F3CEN.html>

Date: April 2025

Pages: 127

Price: US\$ 4,000.00 (Single User License)

ID: EE35B74B7F3CEN

## **Abstracts**

### **Market Overview**

The Europe Liquid Biopsy Market was valued at USD 1.16 billion in 2024 and is expected to grow to USD 1.86 billion by 2030, at a CAGR of 11.72%. This growth is driven by increasing demand for non-invasive diagnostic techniques and the rising incidence of cancer across the region. Liquid biopsy offers a less invasive alternative to traditional tissue biopsies, providing real-time insights into tumor genetics with minimal patient discomfort. As personalized medicine gains traction, liquid biopsy is being increasingly utilized to monitor disease progression and treatment response. Advancements in circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and exosome-based technologies are significantly improving diagnostic sensitivity and specificity. Government and private investments in cancer research, along with the integration of artificial intelligence in data interpretation, are further propelling the market. The growing application of liquid biopsy in early cancer detection, clinical trials, and companion diagnostics is helping to shape a more patient-centric, precision oncology landscape across Europe.

## Key Market Drivers

### Rising Incidence of Cancer

The increasing cancer burden in Europe is a key driver fueling the adoption of liquid biopsy technologies. With around 4.47 million new cancer cases reported in 2022 and an age-standardized rate of 280 per 100,000 individuals, the need for early, accurate, and less invasive diagnostic methods is more critical than ever. Liquid biopsy enables clinicians to detect cancer-related genetic mutations and alterations using bodily fluids such as blood, allowing for real-time disease monitoring, early diagnosis, and evaluation of treatment effectiveness. This non-invasive approach reduces the need for repeated tissue biopsies and aligns with the growing trend of personalized medicine. As cancer prevalence continues to rise, particularly in countries with robust healthcare systems, liquid biopsy is increasingly being integrated into clinical workflows to support improved patient outcomes and targeted therapy decisions.

## Key Market Challenges

### High Cost of Liquid Biopsy Tests

The elevated cost of liquid biopsy tests remains a substantial challenge for the Europe Liquid Biopsy Market. These tests often rely on high-end technologies like next-generation sequencing (NGS), digital PCR, and complex multi-omics platforms that demand advanced lab infrastructure and skilled personnel. Comprehensive tests analyzing multiple biomarkers can be particularly expensive, limiting their affordability for many patients and straining healthcare budgets. Reimbursement policies vary across Europe, with limited or inconsistent coverage posing a barrier to broader clinical adoption. This disparity affects patient access, especially for those in early-stage diagnosis or asymptomatic phases. Consequently, even when liquid biopsy offers clear clinical benefits, its use may be restricted by economic constraints unless reimbursement frameworks evolve to support its widespread integration into standard care.

## Key Market Trends

### Integration of Liquid Biopsy with Companion Diagnostics

The combination of liquid biopsy and companion diagnostics is becoming a

transformative trend in the Europe Liquid Biopsy Market. Companion diagnostics enable the identification of patients most likely to benefit from specific therapies by detecting relevant genetic biomarkers. When coupled with liquid biopsy, these diagnostics become more accessible, non-invasive, and practical for continuous monitoring. This approach supports the rising demand for precision oncology, allowing for tailored therapies and real-time adjustments based on the patient's evolving tumor profile. Pharmaceutical companies are increasingly collaborating with diagnostics developers to create integrated drug-diagnostic platforms, which are being utilized in both clinical trials and routine care. Regulatory support and the ability to track resistance mutations and tumor evolution further enhance the utility of these solutions. This trend is central to advancing precision medicine in Europe, improving treatment efficacy, and minimizing costs from ineffective therapies.

### Key Market Players

QIAGEN N.V.

Epigenomics AG

Inivata Ltd.

Sysmex Inostics GmbH

Stilla Technologies

Novigenix SA

Eurofins Genomics Europe

Chronix Biomedical GmbH

Genseq Ltd.

Blueberry Therapeutics Ltd.

### Report Scope:

In this report, the Europe Liquid Biopsy Market has been segmented into the following

*Europe Liquid Biopsy Market By Offering (Testing Services, Kits, Platform, Other Consumables), By Technology (...)*

categories, in addition to the industry trends which have also been detailed below:

Europe Liquid Biopsy Market, By Offering:

Testing Services

Kits

Platform

Other Consumables

Europe Liquid Biopsy Market, By Technology:

Polymerase Chain Reaction (PCR)

Next Generation Sequencing (NGS)

Others

Europe Liquid Biopsy Market, By Application:

Oncological

Non-Oncological

Europe Liquid Biopsy Market, By End User:

Clinical Laboratories

Academic & Research Institutes

Pharmaceutical & Biotechnology Companies

Europe Liquid Biopsy Market, By Country:

Germany

France

United Kingdom

Italy

Spain

Russia

Poland

Bulgaria

Finland

Portugal

## Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Europe Liquid Biopsy Market.

## Available Customizations:

Europe Liquid Biopsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

## Company Information

Detailed analysis and profiling of additional market players (up to five).

## Contents

### 1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
  - 1.2.1. Markets Covered
  - 1.2.2. Years Considered for Study
  - 1.2.3. Key Market Segmentations

### 2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

### 3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, and Trends

### 4. VOICE OF CUSTOMER

### 5. EUROPE LIQUID BIOPSY MARKET OUTLOOK

- 5.1. Market Size & Forecast
  - 5.1.1. By Value
- 5.2. Market Share & Forecast
  - 5.2.1. By Offering (Testing Services, Kits, Platform, Other Consumables)
  - 5.2.2. By Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Others)
  - 5.2.3. By Application (Oncological, Non-Oncological)

5.2.4. By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies)

5.2.5. By Country

5.2.6. By Company (2024)

5.3. Market Map

## **6. GERMANY LIQUID BIOPSY MARKET OUTLOOK**

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Offering

6.2.2. By Technology

6.2.3. By Application

6.2.4. By End User

## **7. FRANCE LIQUID BIOPSY MARKET OUTLOOK**

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Offering

7.2.2. By Technology

7.2.3. By Application

7.2.4. By End User

## **8. UNITED KINGDOM LIQUID BIOPSY MARKET OUTLOOK**

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Offering

8.2.2. By Technology

8.2.3. By Application

8.2.4. By End User

## **9. ITALY LIQUID BIOPSY MARKET OUTLOOK**

9.1. Market Size & Forecast

- 9.1.1. By Value
- 9.2. Market Share & Forecast
  - 9.2.1. By Offering
  - 9.2.2. By Technology
  - 9.2.3. By Application
  - 9.2.4. By End User

## **10. SPAIN LIQUID BIOPSY MARKET OUTLOOK**

- 10.1. Market Size & Forecast
  - 10.1.1. By Value
- 10.2. Market Share & Forecast
  - 10.2.1. By Offering
  - 10.2.2. By Technology
  - 10.2.3. By Application
  - 10.2.4. By End User

## **11. RUSSIA LIQUID BIOPSY MARKET OUTLOOK**

- 11.1. Market Size & Forecast
  - 11.1.1. By Value
- 11.2. Market Share & Forecast
  - 11.2.1. By Offering
  - 11.2.2. By Technology
  - 11.2.3. By Application
  - 11.2.4. By End User

## **12. POLAND LIQUID BIOPSY MARKET OUTLOOK**

- 12.1. Market Size & Forecast
  - 12.1.1. By Value
- 12.2. Market Share & Forecast
  - 12.2.1. By Offering
  - 12.2.2. By Technology
  - 12.2.3. By Application
  - 12.2.4. By End User

## **13. BULGARIA LIQUID BIOPSY MARKET OUTLOOK**



### 13.1. Market Size & Forecast

#### 13.1.1. By Value

### 13.2. Market Share & Forecast

#### 13.2.1. By Offering

#### 13.2.2. By Technology

#### 13.2.3. By Application

#### 13.2.4. By End User

## 14. FINLAND LIQUID BIOPSY MARKET OUTLOOK

### 14.1. Market Size & Forecast

#### 14.1.1. By Value

### 14.2. Market Share & Forecast

#### 14.2.1. By Offering

#### 14.2.2. By Technology

#### 14.2.3. By Application

#### 14.2.4. By End User

## 15. PORTUGAL LIQUID BIOPSY MARKET OUTLOOK

### 15.1. Market Size & Forecast

#### 15.1.1. By Value

### 15.2. Market Share & Forecast

#### 15.2.1. By Offering

#### 15.2.2. By Technology

#### 15.2.3. By Application

#### 15.2.4. By End User

## 16. MARKET DYNAMICS

### 16.1. Drivers

### 16.2. Challenges

## 17. MARKET TRENDS & DEVELOPMENTS

### 17.1. Merger & Acquisition (If Any)

### 17.2. Product Launches (If Any)

### 17.3. Recent Developments

## **18. EUROPE LIQUID BIOPSY MARKET: SWOT ANALYSIS**

## **19. PORTERS FIVE FORCES ANALYSIS**

- 19.1. Competition in the Industry
- 19.2. Potential of New Entrants
- 19.3. Power of Suppliers
- 19.4. Power of Customers
- 19.5. Threat of Substitute Products

## **20. COMPETITIVE LANDSCAPE**

- 20.1. QIAGEN N.V.
  - 20.1.1. Business Overview
  - 20.1.2. Company Snapshot
  - 20.1.3. Products & Services
  - 20.1.4. Financials (As Reported)
  - 20.1.5. Recent Developments
  - 20.1.6. Key Personnel Details
  - 20.1.7. SWOT Analysis
- 20.2. Epigenomics AG
- 20.3. Inivata Ltd.
- 20.4. Sysmex Inostics GmbH
- 20.5. Stilla Technologies
- 20.6. Novigenix SA
- 20.7. Eurofins Genomics Europe
- 20.8. Chronix Biomedical GmbH
- 20.9. Genseq Ltd.
- 20.10. Blueberry Therapeutics Ltd.

## **21. STRATEGIC RECOMMENDATIONS**

## **22. ABOUT US & DISCLAIMER**

## I would like to order

Product name: Europe Liquid Biopsy Market By Offering (Testing Services, Kits, Platform, Other Consumables), By Technology (Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Others), By Application (Oncological, Non-Oncological), By End User (Clinical Laboratories, Academic & Research Institutes, Pharmaceutical & Biotechnology Companies), By Country, Competition, Forecast and Opportunities, 2020-2030F

Product link: <https://marketpublishers.com/r/EE35B74B7F3CEN.html>

Price: US\$ 4,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EE35B74B7F3CEN.html>